Tvardi Therapeutics, Inc. (TVRD)
Nasdaq · Healthcare · Biotechnology
$1.14−0.87%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $15.2M
- 52-week range
- $0.93 – $43.65
- 52-week change
- −97.14%
- EPS (trailing)
- −$2.84
- Analyst rating
- 1.8 Buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Net income
- −$18.2M
- Diluted EPS
- −$3.26
From the company’s annual report on SEC EDGAR.
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
Headquarters: Sugar Land, United States · 12 employees · tvarditherapeutics.com